Drug Approval | June 12, 2022
China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer
Tislelizumab is now approved in nine indications in China
Tislelizumab is now approved in nine indications in China
Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools
New Director supports NASDAQ rule on diversity
Nippon Express has provided a pharmaceutical distribution platform with strict temperature control in two ranges -- 2 C to 8 C
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
The drug will be manufactured at the group’s topical facility at Ahmedabad
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
Subscribe To Our Newsletter & Stay Updated
